Skip to content

The effect of adding Nicorandil to the three-drug regimen on the quality of life in patients with Coronary slow blood flow disease

The effect of Aspirin, Statin, Nitrate drug regimen on the quality of life in patients with Coronary slow flow disease and its comparison with the addition of Nicorandil

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221228056964N1
Enrollment
56
Registered
2023-01-17
Start date
2023-01-21
Completion date
Unknown
Last updated
2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Slow flow coronary disease. Other forms of angina pectoris

Interventions

Intervention 1: First arm: conventional three-drug regimen of aspirin 80 mg/day, statin 20 mg/day, and nitroglycerin 2.6 mg twice daily for 2 months. Intervention 2: Second arm: a conventional regimen

Sponsors

Qazvin University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients referred to Bu-Ali Sina Referral Center who are candidates for coronary angiography based on clinical criteria, echocardiography, or other causes except for acute myocardial infarction or its history and complications (such as arrhythmias or conduction disorders), and then using The relevant criteria for diagnosing slow flow coronary syndrome are set for them.

Exclusion criteria

Exclusion criteria: Patients with a history of Myocardial infarction, Coronary artery bypass graft surgery, Percutaneous coronary intervention, Heart failure, Valvular heart disease, connective tissue disorders, Atrio-ventricular conduction disorders, Chronic obstructive pulmonary disease, Electrolyte disturbance, Chronic kidney disease, Anemia, and Systemic Hypertension are excluded from the study. After coronary angiography, patients with coronary slow flow due to secondary causes including Coronary artery ectasia, Coronary artery aneurysm, Coronary artery spasm, Air embolism during the procedure, and Congenital anomalies of coronary arteries are excluded from the study. Patients who do not agree to participate in the plan for any reason or decide to withdraw from the plan at any time.

Design outcomes

Primary

MeasureTime frame
Reduction of patients' symptoms. Timepoint: Before and after the end of the medication period. Method of measurement: Clinical signs and symptoms.

Secondary

MeasureTime frame
Improving the patients quality of life. Timepoint: Before and after the end of the medication period. Method of measurement: McNew Quality of life Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Javadi

Qazvin University of Medical Sciences

javadi.hr@gmail.com+98 28 3333 2930

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026